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ABSTRACT
The efficacy of the combination vaccine of the individual C-terminal fragments of ApxIA, ApxIIA and ApxIIIA of 
Actinobacillus pleuropneumoniae (APP) was evaluated in piglets. Twenty piglets were divided equally into 2 groups (n=10). 
All piglets were intramuscularly primed at 4 week-of-age (0 week post prime inoculation (WPPI)) and were intramuscularly 
boosted at 6 week-of-age (2 WPPI). Group A piglets were inoculated with sterile PBS and group B piglets were inoculated 
with the combination vaccine. Concentrations of each of the C-terminal fragment-specific IgG as determined by ELISA 
were significantly higher in group B than in group A from 2 WPPI until the end of this study. Clinical signs were observed 
from only 10% of group B piglets after the challenge with the mixture of APP serotypes 1, 2 and 5 at 4 WPPI, while 50% 
of group A piglets were protected against APP infections. Overall, intramuscular inoculation with the vaccine candidate 
can efficiently protect piglets against APP infection.
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ABSTRAK
Keberkesanan kombinasi vaksin oleh serpihan terminal-C individu ApxIA, ApxIIA dan ApxIIIA daripada Actinobacillus 
pleuropneumoniae (APP) dinilai pada anak babi. Dua puluh anak babi dibahagikan sama rata kepada 2 kumpulan (n=10). 
Semua anak babi telah mencapai intraotot primer pada umur 4 minggu (0 minggu selepas inokulasi utama (WPPI)) dan 
telah dirangsang intraototnya pada umur 6 minggu (2 WPPI). Anak babi kumpulan A telah diinokulasi dengan PBS steril 
dan anak babi kumpulan B telah diinokulasi dengan vaksin kombinasi. Kepekatan setiap IgG fragmen-tertentu terminal-C 
seperti yang ditetapkan oleh ELISA adalah jauh lebih tinggi dalam kumpulan B daripada kumpulan A daripada 2 WPPI 
sehingga ke penghujung kajian ini. Tanda klinikal diperhatikan pada 10% daripada anak babi kumpulan B selepas 
cabaran dengan campuran serotip APP 1, 2 dan 5 pada 4 WPPI, manakala 50% anak babi kumpulan A dilindungi daripada 
jangkitan APP. Secara keseluruhannya, inokulasi intraotot dengan calon vaksin boleh melindungi anak babi terhadap 
jangkitan APP dengan cekap. 
Kata kunci: Actinobacillus pleuropneumoniae; anak babi; imunisasi; perlindungan; porcine pleuropneumonia 
INTRODUCTION
Porcine pleuropneumonia (PP) is a severe, contagious, 
swine pulmonary disease caused by Actinobacillus 
pleuropneumoniae (APP). This disease affects pigs of all 
ages and has a major impact on economics, ecology and 
animal welfare in the pig-rearing industry (Haesebrouck et 
al. 2004). For control of PP, vaccination is crucial (Fenwick 
& Henry 1994). However, the many serotypes of APP have 
made effective vaccination difficult. Various studies have 
been carried out to identify vaccine candidates for efficient 
cross-protection, such as killed bacterin vaccines and 
subunit vaccines (Blackall et al. 2002; Haesebrouck et al. 
2004; Zhou et al. 2013). These vaccine candidates do not 
prevent colonization and are not widely cross-protective 
(Tumamao et al. 2004). Therefore, further efforts need to 
be made for development of more efficient vaccines.
 Among several virulence factors, Apx [repetitive 
glycine-rich sequences in repeats-in-toxins exotoxins (RTX 
toxins)] toxins are recognized as major virulence factors 
of APP (Haesebrouck et al. 2004; Kamp et al. 1997). The 
importance of Apx toxins in protective immunity against 
PP has been demonstrated in many studies (Haesebrouck 
et al. 2004; Shin et al. 2005). The 15 serotypes of APP 
produce four different Apx toxins including ApxI, ApxII, 
ApxIII and ApxIV (Zhou et al. 2013). ApxIA and ApxIIA 
toxins contribute to hemolytic and cytotoxic functions 
(Frey & Kuhnert 2002). ApxIIIA has no hemolytic activity 
but shows strong cytotoxic activity towards alveolar 
macrophages and neutrophils (Cruijsen et al. 1992; Rycroft 
et al. 1991). In South Korea, serotypes 1, 2 and 5 have 
been known to dominate since 2000 (Kim et al. 2001; Lee 
et al. 2015; Yoo et al. 2014). The objective of this study 
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was to evaluate the efficacy of the combination vaccine of 
the individual C-terminal recombinant proteins of ApxIA, 
ApxIIA and ApxIIIA in order to improve the prevention of 
PP in piglets.
MATERIALS AND METHODS
BACTERIAL STRAINS AND GROWTH CONDITIONS
Wild type APP, serotype 1, HJL6, serotype 2, HJL67 and 
serotype 5, HJL263, were used for amplification of the genes 
encoding each C-terminal fragment of ApxIA, ApxIIA and 
ApxIIIA. In addition, wild type APP isolates, HJL6, HJL67 
and HJL263, were used as the virulent challenge strains. 
These serotypes were kindly supplied by the National 
Veterinary Research and Quarantine Service (Anyang, 
Gyeonggi, South Korea) (Table 1). The strains were grown 
in chocolate agar at 37°C. 
CONSTRUCTION OF ESCHERICHIA COLI STRAINS 
EXPRESSING APXIA, APXIIA AND APXIIIA
Each of the C-terminal fragment gene of ApxIA, ApxIIA 
and ApxIIIA were amplified from APP genomic DNA using 
the specific primers (Table 2). The PCR fragments of each 
gene were digested with restriction enzymes and were 
subsequently cloned into pET21a. These plasmids were 
transformed into E. coli BL21 (DE3) pLysS to create HJL401, 
HJL402 and HJL403. The individual recombinant C-terminal 
fragments were prepared from an affinity purification 
process with nickel-nitrilotriacetic acid-agarose (Qiagen, 
Valencia, CA, USA). The identities of the purified antigens 
were confirmed via sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE). All purified antigens were 
stored at -70°C until use.
PREPARATION OF THE COMBINATION VACCINE
In order to prepare combination vaccine that consists 
of the individual C-terminal fragments, the individual 
C-terminal fragments (consisting of approximately 30 
μg per each C-terminals protein) were resuspended in 10 
mg/mL of aluminum hydroxide, which was used here as a 
parenteral adjuvant. The combination vaccine was stored 
at 4°C until use.
IMMUNIZATION AND SAMPLE COLLECTION
Twenty Large Yorkshire piglets were divided equally into 
two groups. All piglets were intramuscularly primed at 4 
weeks of age (0 week post prime inoculation (WPPI)) and 
were intramuscularly boosted at 6 weeks of age (2 WPPI). 
Group A piglets were inoculated with 2 mL of sterile PBS 
as the control. Group B piglets were inoculated with 2 mL 
of the combination vaccine. Blood samples were collected 
at 0, 2 and 4 WPPI for the evaluation of immune response. 
The animal experiments mentioned in this study were 
conducted with ethics approval (CBU 2011-0017) from the 
Chonbuk National University Animal Ethics Committee 
in accordance with the guidelines of the Korean Council 
on Animal Care.
IMMUNE RESPONSE BY ELISA
IgG concentrations against the individual recombinant 
C-terminal fragments in serum were evaluated by ELISA 
using a modified method from a previous study (Hur 
& Lee 2014). Briefly, sera were diluted 1:100 in PBS. 
The plates were treated with horseradish peroxidase-
conjugated goat anti-swine IgG antibody. Enzymatic 
reactions were produced through the addition of substrate 
containing o-phenylenediamine (Sigma-Aldrich, St. 
Louis, MO, USA) and measured using an automated ELISA 
spectrophotometer (Thermo Scientific Multiskan GO, 
Thermo Fisher Scientific Oy, Ratastie, Vantaa, Finland) 
at 492 nm. A standard curve was generated to represent 
the relationship between the concentrations of the 
standards and their absorbance, and the concentration 
of antibodies in each sample was determined using this 
curve. The results of ELISA are expressed as the mean ± 
standard deviation.
TABLE 1. Bacterial strains and plasmids used for this study
Strain/plasmid Description Source of reference
Strains
 E. coli
BL21(DE3)pLysS
HJL401
HJL402
HJL403
F–, ompT, hsdS
B
(r
B
–,m
B
–), dcm, gal, λ(DE3), pLysS, Cmr
E. coli BL21 with pET21a-ApxIA C-terminal 
E. coli BL21 with pET21a-ApxIIA C-terminal 
E. coli BL21 with pET21a-ApxIIIA C-terminal 
Lab stock
This study
This study
This study
 A. pleuropneumoniae
HJL6
HJL67
HJL263
Actinobacillus pleuropneumoniae serotype 1
Actinobacillus pleuropneumoniae serotype 2
Actinobacillus pleuropneumoniae serotype 5
Lab stock
Lab stock
Lab stock
Plasmids
pET21a IPTG-inducible expression vector; Kmr Novagen
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CHALLENGE EXPERIMENTS
All piglets were challenged intranasally with the mixture of 
HJL6, HJL67 and HJL263 at 4 WPPI. A total of 6 × 109 CFU in 
2 mL of sterile PBS were used as challenge dose for piglets. 
All challenged piglets were monitored daily for mortality 
and abnormal behavior during 7 days after the challenge. 
At 7 days after challenge, all piglets were euthanized and 
challenge strains were examined from the swabs of lung 
observed abnormally in gross examination. The swabs were 
streaked onto chocolate agar and incubated at 37°C for 24 
h. Challenge strains were confirmed by PCR (Table 2) using 
APP- , type 1-, type 2- and type 5-specific primers (Jessing et 
al. 2008, 2003). If isolates from the lung swab contained PCR 
amplicon products from at least one of the serotype-specific 
primers (Table 2) according to the previously described 
method (Jessing et al. 2008, 2003), the pneumonic lung 
sign was classified as induced by the challenge.
STATISTICAL ANALYSIS
Analyses were performed with SPSS version 16.0 software 
(SPSS, Chicago, IL). A Student’s t test was used to analyze 
statistical differences in the immune responses between 
the immunized groups and an unimmunized control group. 
Statistical significance was determined at p<0.05.
RESULTS
PRODUCTION OF RECOMBINANT PROTEINS
SDS-PAGE analysis of proteins purified after expression in 
HJL401, HJL402 and HJL403 showed prominent bands at 
approximately 50, 43.1 and 50 kDa, respectively (Figure 1).
Humoral immune response in immunized piglets
TABLE 2. PCR primers used in this study and their product sizes 
Name Sequence(5′→3′) Size 
(bp)
Accession 
number
Reference
Apx IAC-F CGGGATCC GGT ATT ATT TCA 1293 GQ369732 This study
Apx IAC-R GTCGAC AGT ACC ATC GCT GC
Apx IIAC-F ATTCGGATCC CAA GGT TAT GA 1110 AY736188 This study
Apx IIAC-R GCTTGTCGAC TGT AAT AGA ATC ATT T
Apx IIIAC-F GGGATCC GCA CCA ATT ACT TT 1293 X68815 This study
Apx IIIAC-R TGTCGAC AAG CAC ATT AAA ACC
HPF AAG GTT GAT ATG TCC GCA CC
956 AB007587.1  Jessing et al. 2003
HPR CAC CGA TTA CGC CTT GCC A
Ap1F GGG CAA GCC TCT GCT CGT AA
754 AF518558.1 Jessing et al. 2008
Ap1R GAA AGA ACC AAG CTC CTG CAA T
Ap2F ACT ATG GCA ATC AGT CGA TTC AT
500 AY357726.1  Jessing et al. 2003
Ap2R CCT AAT CGG AAA CGC CAT TCT G
Ap5F TTT ATC ACT ATC ACC GTC CAC ACC T
1,100 AF053723.1 Jessing et al. 2003
Ap5R CAT TCG GGT CTT GTG GCT ACT AA
Underlines indicate the sites of restriction enzymes, such as BamHI and SalI
FIGURE 1. Expression and purification of each C-terminal fragment 
of ApxIA, ApxIIA or ApxIIIA. Coomassie blue-stained SDS-
PAGE gel showing each C-terminal fragments of ApxIA, ApxIIA 
or ApxIIIA purified from HJL401, HJL402 and HJL403 using 
His-tag affinity chromatography. Lanes: M, protein marker; IA, 
ApxIA- C-terminal fragment; IIA, ApxIIA- C-terminal fragment; 
and IIIA, ApxIIIA- C-terminal fragment 
 In Figure 2, antibody responses against the 
recombinant C-terminal fragments are shown. Serum IgG 
concentrations against all the individual antigens in group 
B were significantly increased compared to those of group 
A from 2 WPPI until the end of the study (p<0.05). 
PROTECTION OF PIGLETS AGAINST VIRULENT CHALLENGE
All piglets were intranasally challenged with the mixture 
of the challenge strains at 4 WPPI. Among 10 piglets of 
group A, 2 were dead within 7 days after challenge and the 
challenge strains were isolated from lung swab of 5 piglets 
(containing dead piglets) with pneumonic lung lesions 
observed upon gross examination. Among 10 piglets of 
group B, however, the lungs of 9 piglets were observed 
as normal in gross examination. 
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DISCUSSION
Among available vaccines for APP, the most commonly 
used are formalin-killed APP bacterin (Liao et al. 2003). 
These vaccines do not effectively prevent colonization and 
are not widely cross protective (Tumamao et al. 2004). As 
other pathogenic bacteria of multiple serotypes, a major 
point in the prevention of APP infections is to identify 
conserved antigens or proteins involved in immunogenicity, 
which may provide cross-protection against distinct APP 
serotype infections (Chen et al. 2012; Haesebrouck et al. 
2004). The Apx toxins, such as ApxI, ApxII and ApxIII 
are virulence factors that play a predominant role in the 
pathogenesis of APP. Since each of the Apx toxins confer 
only partial protection against PP and the distribution of 
Apx toxins vary among the different serotypes (Lu et al. 
2011; Ramjeet et al. 2008), a combination of three Apx 
toxins in the vaccine constructs is necessary to protect 
against the broad range of APP infections. 
 In the present study, the individual B-subunit proteins 
of Apx IA, Apx IIA and Apx IIIA were constructed and the 
efficacy of the combination vaccine against APP infections 
was examined in piglet models. Secretory IgA transported 
and secreted across the mucosal epithelium into the lumen 
can inhibit attachment of microorganisms and/or neutralize 
exotoxins (Holmgren et al 2005; MacDonald 2003). 
This defense mechanism against pulmonary bacterial 
infection depends on the clearance of the pathogens from 
the respiratory tract and mucosal immunity by systemic 
immune response is necessary for effective vaccination 
against PP (Haesebrouck et al. 2004). We confirmed that the 
intramuscular inoculation procedure effectively stimulated 
all the antigen-specific IgG immune response. Following 
intranasal inoculation with the mixture of wild type virulent 
APP strains, the survival ratio in each group of piglets 
was examined and 90% of the immunized piglets were 
protected against virulent APP infection after challenge, 
while only 50% of non-immunized group of piglets 
were protected. This finding showed that intramuscular 
immunization with our combination vaccine can effectively 
protect the challenge strain.
 In conclusion, the systemic immune response was 
markedly induced by intramuscular immunization with the 
combination vaccine of individual C-terminal fragments of 
three Apx toxins. Clinical signs were observed in a total of 
only 10% from intramuscular-primed and intramuscular-
boosted piglets after challenge with virulent APP strains. 
However, 50% clinical signs were observed in the control. 
Therefore, intramuscular immunization of piglets with our 
combination vaccine candidate may effectively protect 
piglets from PP caused by APP.
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